{"id":"NCT00513682","sponsor":"Forest Laboratories","briefTitle":"Efficacy and Safety of Ultrase® MT20 in Improving the Coefficient of Fat Absorption (CFA) in Children With Cystic Fibrosis (CF) and Pancreatic Insufficiency (PI)","officialTitle":"Efficacy and Safety of Ultrase® MT20 in Improving the Coefficient of Fat Absorption (CFA%) in Children With Cystic Fibrosis (CF) and Pancreatic Insufficiency (PI)","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2007-07","primaryCompletion":"2008-03","completion":"2008-04","firstPosted":"2007-08-09","resultsPosted":"2014-04-10","lastUpdate":"2017-03-16"},"enrollment":9,"design":{"allocation":"NA","model":"SINGLE_GROUP","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Cystic Fibrosis","Pancreatic Insufficiency"],"interventions":[{"type":"DRUG","name":"Ultrase® MT20","otherNames":[]}],"arms":[{"label":"Ultrase® MT20","type":"EXPERIMENTAL"}],"summary":"This is a Phase III, multicenter, open-label study, that will evaluate the improvement of nutrient absorption when participants will receive Ultrase® MT20. This study is sponsored by Aptalis (formerly Axcan). This study is performed in children from 7 to 11 years old.","primaryOutcome":{"measure":"Percent Coefficient of Fat Absorption (CFA)","timeFrame":"Day 3 to Day 5 or Day 6 during washout phase and treatment phase","effectByArm":[{"arm":"Ultrase® MT20 Washout Phase","deltaMin":34.5,"sd":21.35},{"arm":"Ultrase® MT20 Treatment Phase","deltaMin":82.7,"sd":13.25}],"pValues":[{"comp":"OG000 vs OG001","p":"0.0013"}]},"eligibility":{"minAge":"7 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":10,"exclusionCount":17},"locations":{"siteCount":3,"countries":["United States"]},"refs":{"pmids":[],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":0,"n":9},"commonTop":["Abdominal pain","Abnormal faeces","Headache","Nasal congestion","Abdominal discomfort"]}}